AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Halozyme Therapeutics CEO Helen Torley sells, buys shares in July 2025.
ByAinvest
Thursday, Jul 10, 2025 7:49 pm ET1min read
Halozyme Therapeutics, Inc. [HALO] has announced that Director, President and CEO Torley Helen has engaged in several transactions involving the sale and purchase of company shares. On July 8, 2025, she sold 3,598 shares at $54.48 per share. On July 10, 2025, she sold 4,254 shares at $56.74 per share and bought 20,000 shares at $8.11 per share. On July 9, 2025, she sold 2,092 shares at $57.08 per share and 19,792 shares at $56.43 per share, while also purchasing 20,000 shares at $8.11 per share. On July 10, 2025, she sold 15,746 shares at $57.62 per share and on July 8, 2025, she sold 16,602 shares at $55.74 per share.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet